Results 161 to 170 of about 21,560 (287)

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén   +16 more
wiley   +1 more source

GPER1 activation regulates renal purinergic P2Y<sub>2</sub> receptor natriuretic pathway. [PDF]

open access: yesAm J Physiol Regul Integr Comp Physiol
Kulthinee S   +3 more
europepmc   +1 more source

D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors [PDF]

open access: bronze, 2001
Maria Augusta Vieira‐Coelho   +3 more
openalex   +1 more source

The kidney in congestive heart failure: ‘are natriuresis, sodium, and diuretics really the good, the bad and the ugly?’

open access: yesEuropean Journal of Heart Failure, 2014
F. Verbrugge   +6 more
semanticscholar   +1 more source

Left atrial function in uraemic patients: Four‐dimensional automatic left atrial quantitative technology study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1316-1325, April 2025.
Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy